We are live on ! Find out more
SYRS

Syros Pharmaceuticals, Inc. Common Stock
SYRS

Delisted

SYRS was delisted on the 19th of March, 2025.

Back to rankings

48 hedge funds and large institutions have $47.9M invested in Syros Pharmaceuticals, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 8

43% more capital invested

Capital invested by funds: $33.5M → $47.9M (+$14.5M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

9% less funds holding

Funds holding: 53 → 48 (-5)

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

Holders
48
Holders Change
-5
Holders Change %
-9.43%
% of All Funds
0.76%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
3
Increased
13
Reduced
8
Closed
6
Calls
$1.04M
Puts
–
Net Calls
+$1.04M
Net Calls Change
+$212K

Top Buyers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
+$3.1M
2
CA
CHI Advisors
New York
+$1.99M
3
APM
Avidity Partners Management
Texas
+$438K
4
BlackRock
BlackRock
New York
+$130K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$116K

Top Sellers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
-$86K
2
Two Sigma Investments
Two Sigma Investments
New York
-$61.7K
3
Millennium Management
Millennium Management
New York
-$40.4K
4
ECM
ExodusPoint Capital Management
New York
-$38.4K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$37.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
26
T. Rowe Price Associates
Maryland
$90K – – –
1CM
27
1492 Capital Management
Wisconsin
$85.9K – – –
CGL
28
Clarius Group LLC
Washington
$73.5K +$69.7K +18,620 New
CIBC Asset Management
29
CIBC Asset Management
Ontario, Canada
$60.8K – – –
HighTower Advisors
30
HighTower Advisors
Illinois
$59K – – –
Morgan Stanley
31
Morgan Stanley
New York
$18.6K -$7.02K -1,876 -29%
EDRH
32
Edmond de Rothschild Holding
Switzerland
$17.3K – – –
Group One Trading
33
Group One Trading
Illinois
$5.05K – – –
PNC Financial Services Group
34
PNC Financial Services Group
Pennsylvania
$4.33K – – –
UBS Group
35
UBS Group
Switzerland
$4.32K +$4.09K +1,093 New
JP Morgan Chase
36
JP Morgan Chase
New York
$4.25K +$1.8K +481 +81%
Royal Bank of Canada
37
Royal Bank of Canada
Ontario, Canada
$4K -$2.09K -559 -37%
Russell Investments Group
38
Russell Investments Group
United Kingdom
$2.96K – – –
RhumbLine Advisers
39
RhumbLine Advisers
Massachusetts
$2.6K – – –
Wells Fargo
40
Wells Fargo
California
$2.53K -$389 -104 -14%
IA
41
IFP Advisors
Florida
$1.73K – – –
Fidelity Investments
42
Fidelity Investments
Massachusetts
$1.37K +$932 +249 +257%
Osaic Holdings
43
Osaic Holdings
Arizona
$1.17K +$273 +73 +33%
Fifth Third Bancorp
44
Fifth Third Bancorp
Ohio
$510 – – –
SIS
45
Sound Income Strategies
Florida
$300 – – –
Bank of America
46
Bank of America
North Carolina
$269 -$4 -1 -1%
FFA
47
Farther Finance Advisors
California
$79 – – –
GCP
48
GSA Capital Partners
United Kingdom
– -$86K -27,460 Closed
Two Sigma Investments
49
Two Sigma Investments
New York
– -$61.7K -19,584 Closed
Millennium Management
50
Millennium Management
New York
– -$40.4K -12,825 Closed
1
2
3

SYRS Hedge Fund Activity: Q3 2023 in Review

48 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q3 2023, worth a combined $47.9M — up 43% from $33.5M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of SYRS and 3 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 13 added.

The largest buyer was Deep Track Capital, opening a new position worth an estimated $3.1M. The largest seller was GSA Capital Partners, exiting entirely with an estimated $86K sold.

  • 48 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q3 2023, down from 53 in Q2 2023.
  • Funds reported $47.9M of Syros Pharmaceuticals, Inc. Common Stock stock for Q3 2023, up 43% quarter-over-quarter.
  • 3 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q3 2023 and 6 closed out, a net change of -3 holders.
  • The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q3 2023 was Deep Track Capital, an estimated $3.1M added.
  • The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q3 2023 was GSA Capital Partners, an estimated $86K sold.

Based on aggregated 13F filings for Q3 2023.